Core Insights - Castle Biosciences is presenting data on its DecisionDx®-Melanoma test and pipeline atopic dermatitis gene expression profile test at the 25th Annual Fall Clinical Dermatology Conference [1] - The DecisionDx-Melanoma test has shown clinically significant risk stratification across various histological subtypes of melanoma, confirming its clinical value [2][4] - The pipeline atopic dermatitis test aims to improve treatment decision-making by classifying patients based on their underlying disease biology [5] DecisionDx-Melanoma Insights - The DecisionDx-Melanoma test utilizes a 31-gene expression profile to stratify melanoma-specific survival across different tumor subtypes, demonstrating significant differences in five-year survival rates [4][6] - In a cohort of 13,560 patients, five-year melanoma-specific survival was 98.5% for Class 1A (lowest risk) and 82.3% for Class 2B (highest risk) patients with nodular melanoma [4] - The test can identify early-stage melanoma patients at higher risk of distant metastasis, with Class 2B patients showing significantly higher rates of metastasis compared to Class 1A patients [4] Atopic Dermatitis Pipeline Insights - The pipeline atopic dermatitis test classifies patients into Th2 Molecular Profile or JAKi Responder Profile, aiming to guide systemic therapy selection [5] - Data indicates that patients with a JAKi responder profile experience rapid and deep responses to JAK inhibitors, potentially improving treatment outcomes [5] - The test seeks to shift atopic dermatitis care from trial-and-error prescribing to more personalized treatment approaches, enhancing patient satisfaction and reducing healthcare costs [5] Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a portfolio that includes tests for skin cancers and other diseases [7][8] - The company has conducted over 210,000 orders for the DecisionDx-Melanoma test, indicating strong market adoption and clinical relevance [6]

Core Insights - The DecisionDx-SCC test significantly outperforms current staging systems in predicting local recurrence and metastasis for NCCN high-risk patients with cutaneous squamous cell carcinoma (SCC) [1][3][4] - The test provides individualized risk predictions that align with treatment decision-making for adjuvant radiation therapy (ART) and surveillance imaging [2][5] Study Findings - The first study demonstrates that DecisionDx-SCC predicts local recurrence in high-risk patients post-Mohs resection, adding a third validated use to the test [2][4] - The second study confirms that clinicians utilize test results to guide recommendations for ART and surveillance imaging based on individual patient risk [2][5] Clinical Implications - DecisionDx-SCC effectively stratifies risk among 414 NCCN high-risk SCC patients, showing three-year local recurrence-free survival rates of 95.3% for low risk (Class 1), 85.5% for higher risk (Class 2A), and 71.4% for highest risk (Class 2B) [4] - The test's predictive accuracy improves when combined with established clinicopathologic factors, enhancing risk stratification beyond traditional staging systems [4][5] Clinician Insights - A survey of 244 clinicians revealed that most recommend ART for patients with a ≥20% risk of local recurrence or metastasis and surveillance imaging for those with a ≥10% risk of metastasis [4][5] - Clinicians reported that Class 2B test results are among the most critical factors in management decisions for ART [5] Company Overview - Castle Biosciences, Inc. focuses on innovative diagnostic tests that guide patient care, with a portfolio that includes tests for skin cancers and other diseases with high clinical need [7][8] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [7]